The reason a price desk exists is that most people buying these drugs are paying for them themselves, and the national benefits survey now puts a figure on how many. In 2025, nearly one in five — 19 percent — of large firms offering health benefits covered GLP-1 agonists when used primarily for weight loss [1]. Four in five did not. That single number is the reason the figures on the sellers ranked here matter at all: for most readers there is no formulary in the way, only a checkout.
What the 19 percent does and does not cover
The denominator deserves attention before the number travels. It is large firms that offer health benefits, and it is coverage for weight loss specifically. Coverage when the same molecule is prescribed for type 2 diabetes is an older and far broader arrangement, and it is not what this figure describes. A reader with diabetes and a reader seeking weight loss can be prescribed the identical drug and meet completely different bills, which is why a telehealth seller’s price is a cash price by default — the thing our cost calculator is built to total.
The surrounding numbers explain the direction
The same survey found the average annual family premium reached $26,993, up $1,408 or 6 percent in a year. Covered workers contributed 16 percent of the single-coverage premium, averaging $1,440, and 26 percent of family coverage, averaging $6,850. Among workers with a general annual deductible for single coverage, that deductible averaged $1,886. 36% of large firms said prescription drug prices contributed “a great deal” toward premium increases, and 45% of firms offering benefits reported their employees had a high or moderate level of concern about the affordability of cost sharing. On the benefit itself the split is 19% against 81%.
Read together, those figures describe an employer market under pressure from drug prices while deciding whether to add a drug class that is expensive by design. Nothing about that combination suggests the 19 percent is about to become a majority quickly.
What it means at a checkout
If you are in the four in five, the published price is the price, which puts the weight on whether it is the whole price. That is where the gap on this market sits: a membership billed beside the medication, a plan term that is not a calendar month, an opening figure that lasts one fill. We count those across the roster in the headline against the billed price, and the sellers whose advertised figure survives contact with a checkout are the ones worth shortlisting in what six months actually comes to.